John is a founding member of Mintz Levin's Electronic Discovery Practice Group and he serves as Practice Coordinator for this Group. John is also an active member of the Product Liability and Complex Tort Litigation Practice Group. John is a member of Mintz Levin's Hiring and Diversity Committees. In 2011, John was named a "Rising Star" by Massachusetts Super Lawyers in a supplement of Boston Magazine and in 2012 was named an "Up and Coming Lawyer" by Massachusetts Lawyers Weekly and the Massachusetts Bar Association.
John has a diverse litigation and counseling practice with a particular focus on products liability and contract and licensing disputes for life sciences companies. Particularly, John serves as national coordinating, strategy, and discovery counsel for pharmaceutical clients involved in serial litigation. In this role, John advises on liability minimization and prevention strategies as well as information governance and the design and execution of companywide and multinational discovery plans. John also writes and speaks regularly on discovery law and practice in state and federal courts.
Some of John's recent representative matters include:
· Currently representing a publicly-traded biotechnology company as national coordinating, strategy, and discovery counsel in product liability disputes initiated in various state, federal, and international courts involving two FDA-approved pharmaceutical drugs for the treatment of lymphoma and multiple sclerosis.
· Successfully represented a publicly-traded biotechnology company in a wrongful death action brought in state court by the estate of a patient who died following post-market treatment with an FDA-approved pharmaceutical drug.
· Successfully represented and managed discovery for a leading biotechnology company in a claim brought pro se by a patient who alleged to have suffered an adverse reaction to a placebo formula during participation in a clinical trial study.
· Successfully obtained a favorable settlement for a publicly-traded diagnostic manufacturer in a "bet the company" arbitration premised on claims that the manufacturer's licensee had failed to develop the manufacturer's microRNA-based products as required by the governing licensing agreement.
· Successfully advised a publicly-traded pharmaceutical company with respect to divestment of its cardiovascular research and development pipeline as well as a favorable wind-up of an associated collaboration with another pharmaceutical company.
· Successfully obtained declaratory relief for a publicly-traded biotechnology company in an arbitration brought against a collaboration partner seeking to withhold decision-making and development rights in contravention of the governing collaboration agreement associated with a multi-billion dollar FDA-approved treatment for cancer and rheumatoid arthritis.
John also has extensive pro bono experience advising victims of domestic violence and organizations that serve these victims in privacy matters and information governance.
Outside of the office, John is a part-time faculty member at Boston University School of Law, where he teaches in the Legal Writing Program. In 2011, he was appointed to the Massachusetts Bar Association task force to address law school graduates' difficulty finding jobs in the struggling economy. John is also a member of the Board of Directors at Fenway Health as well as its Board of Visitors and the Steering Committee of its Young Leaders Council.